Skip to main content
Top
Published in: Osteoporosis International 4/2014

01-04-2014 | Case Report

Nonuremic calciphylaxis precipitated by teriparatide [rhPTH(1–34)] therapy in the setting of chronic warfarin and glucocorticoid treatment

Authors: E. K. Spanakis, D. E. Sellmeyer

Published in: Osteoporosis International | Issue 4/2014

Login to get access

Abstract

Calciphylaxis occurs rarely in the absence of end stage renal disease. Predisposing factors for nonuremic calciphylaxis (NUC) include hyperparathyroidism, coagulopathies, connective tissue disease, liver disease, glucocorticoid use, and malignancy. Warfarin can facilitate vascular calcification by reducing vitamin K-dependent carboxylation of matrix-Gla proteins. An 86-year-old Caucasian woman with a history of polymyalgia rheumatica, two spontaneous deep venous thromboses (DVTs) and multiple fractures was treated with calcium, vitamin D, prednisone, and warfarin. The patient's low bone density was treated initially with estrogen, then oral bisphosphonate, which was discontinued due to upper gastrointestinal symptoms. Nasal calcitonin was initiated. After 10 years of calcitonin treatment, she was changed to teriparatide. Two months after initiating teriparatide, she developed lower extremity edema and painful erythematous nodular lesions on her calves bilaterally, that progressed to necrotic ulcers despite antibiotic therapy. Biopsy of the lesions showed calcification in the media of small blood vessels and subcutaneous fat with fat necrosis, consistent with calciphylaxis. Teriparatide was discontinued. Aggressive wound care, antibiotics, and intravenous zoledronic acid were initiated. With cessation of teriparatide therapy and intensive wound care, the patient's lesions resolved over 8 months. We report the first case of NUC precipitated by teriparatide therapy. Our patient had multiple underlying predisposing factors including a connective tissue disorder, glucocorticoid therapy, warfarin use, and possible underlying coagulopathy given her history of multiple DVTs. In such patients, alternative osteoporosis therapies may be preferred.
Literature
1.
go back to reference Nigwekar SU, Wolf M, Sterns RH, Hix JK (2008) Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc of Nephrol: CJASN 3:1139–1143CrossRef Nigwekar SU, Wolf M, Sterns RH, Hix JK (2008) Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc of Nephrol: CJASN 3:1139–1143CrossRef
2.
go back to reference Bryant JHWW (1898) A case of calcification of the arteries and obliterative endarteritis associated with hydronephrosis in a child aged six months. Guy's Hosp Rep 55:17–20 Bryant JHWW (1898) A case of calcification of the arteries and obliterative endarteritis associated with hydronephrosis in a child aged six months. Guy's Hosp Rep 55:17–20
3.
go back to reference Selye H, Gabbiani G, Strebel R (1962) Sensitization to calciphylaxis by endogenous parathyroid hormone. Endocrinology 71:554–558PubMedCrossRef Selye H, Gabbiani G, Strebel R (1962) Sensitization to calciphylaxis by endogenous parathyroid hormone. Endocrinology 71:554–558PubMedCrossRef
4.
go back to reference Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441PubMedCrossRef Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441PubMedCrossRef
5.
go back to reference Angelis M, Wong LL, Myers SA, Wong LM (1997) Calciphylaxis in patients on hemodialysis: a prevalence study. Surgery 122:1083–1089, discussion 1089–1090PubMedCrossRef Angelis M, Wong LL, Myers SA, Wong LM (1997) Calciphylaxis in patients on hemodialysis: a prevalence study. Surgery 122:1083–1089, discussion 1089–1090PubMedCrossRef
6.
go back to reference Budisavljevic MN, Cheek D, Ploth DW (1996) Calciphylaxis in chronic renal failure. J Am Soc Nephrol: JASN 7:978–982PubMed Budisavljevic MN, Cheek D, Ploth DW (1996) Calciphylaxis in chronic renal failure. J Am Soc Nephrol: JASN 7:978–982PubMed
7.
go back to reference Weenig RH (2008) Pathogenesis of calciphylaxis: Hans Selye to nuclear factor kappa-B. J Am Acad Dermatol 58:458–471PubMedCrossRef Weenig RH (2008) Pathogenesis of calciphylaxis: Hans Selye to nuclear factor kappa-B. J Am Acad Dermatol 58:458–471PubMedCrossRef
8.
go back to reference Weenig RH, Sewell LD, Davis MD, McCarthy JT, Pittelkow MR (2007) Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol 56:569–579PubMedCrossRef Weenig RH, Sewell LD, Davis MD, McCarthy JT, Pittelkow MR (2007) Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol 56:569–579PubMedCrossRef
9.
go back to reference Rogers NM, Teubner DJ, Coates PT (2007) Calcific uremic arteriolopathy: advances in pathogenesis and treatment. Semin Dialysis 20:150–157CrossRef Rogers NM, Teubner DJ, Coates PT (2007) Calcific uremic arteriolopathy: advances in pathogenesis and treatment. Semin Dialysis 20:150–157CrossRef
10.
go back to reference Vedvyas C, Winterfield LS, Vleugels RA (2012) Calciphylaxis: a systematic review of existing and emerging therapies. J Am Acad Dermatol 67:e253–e260PubMedCrossRef Vedvyas C, Winterfield LS, Vleugels RA (2012) Calciphylaxis: a systematic review of existing and emerging therapies. J Am Acad Dermatol 67:e253–e260PubMedCrossRef
11.
go back to reference Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR, Chandrasekhar S, Martin TJ, Onyia JE (2001) Catabolic effects of continuous human PTH (1–38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 142:4047–4054PubMed Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR, Chandrasekhar S, Martin TJ, Onyia JE (2001) Catabolic effects of continuous human PTH (1–38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 142:4047–4054PubMed
12.
go back to reference Asobie N, Wong E, Cook MG (2008) Calciphylaxis in a diabetic patient provoked by warfarin therapy. Clin Exp Dermatol 33:342–344PubMedCrossRef Asobie N, Wong E, Cook MG (2008) Calciphylaxis in a diabetic patient provoked by warfarin therapy. Clin Exp Dermatol 33:342–344PubMedCrossRef
13.
go back to reference Wallin R, Cain D, Sane DC (1999) Matrix Gla protein synthesis and gamma-carboxylation in the aortic vessel wall and proliferating vascular smooth muscle cells—a cell system which resembles the system in bone cells. Thromb Haemost 82:1764–1767PubMed Wallin R, Cain D, Sane DC (1999) Matrix Gla protein synthesis and gamma-carboxylation in the aortic vessel wall and proliferating vascular smooth muscle cells—a cell system which resembles the system in bone cells. Thromb Haemost 82:1764–1767PubMed
15.
go back to reference Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, Muller-Esterl W, Schinke T, Jahnen-Dechent W (2003) The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Investig 112:357–366PubMedCentralPubMedCrossRef Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, Muller-Esterl W, Schinke T, Jahnen-Dechent W (2003) The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Investig 112:357–366PubMedCentralPubMedCrossRef
16.
go back to reference Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G (1997) Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386:78–81PubMedCrossRef Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G (1997) Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386:78–81PubMedCrossRef
17.
go back to reference Vedvyas C, Winterfield LS, Vleugels RA (2011) Calciphylaxis: a systematic review of existing and emerging therapies. J Am Acad Dermatol 67(6):e253–e260PubMedCrossRef Vedvyas C, Winterfield LS, Vleugels RA (2011) Calciphylaxis: a systematic review of existing and emerging therapies. J Am Acad Dermatol 67(6):e253–e260PubMedCrossRef
18.
go back to reference Fine A, Zacharias J (2002) Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int 61:2210–2217PubMedCrossRef Fine A, Zacharias J (2002) Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int 61:2210–2217PubMedCrossRef
19.
go back to reference Mohammed IA, Sekar V, Bubtana AJ, Mitra S, Hutchison AJ (2008) Proximal calciphylaxis treated with calcimimetic 'Cinacalcet'. Nephrol Dial Transplant 23:387–389PubMedCrossRef Mohammed IA, Sekar V, Bubtana AJ, Mitra S, Hutchison AJ (2008) Proximal calciphylaxis treated with calcimimetic 'Cinacalcet'. Nephrol Dial Transplant 23:387–389PubMedCrossRef
20.
go back to reference Kang AS, McCarthy JT, Rowland C, Farley DR, van Heerden JA (2000) Is calciphylaxis best treated surgically or medically? Surgery 128:967–971, discussion 971–962PubMedCrossRef Kang AS, McCarthy JT, Rowland C, Farley DR, van Heerden JA (2000) Is calciphylaxis best treated surgically or medically? Surgery 128:967–971, discussion 971–962PubMedCrossRef
21.
go back to reference Cecchini MG, Felix R, Fleisch H, Cooper PH (1987) Effect of bisphosphonates on proliferation and viability of mouse bone marrow-derived macrophages. J Bone Miner Res: Off J Am Soc Bone Miner Res 2:135–142CrossRef Cecchini MG, Felix R, Fleisch H, Cooper PH (1987) Effect of bisphosphonates on proliferation and viability of mouse bone marrow-derived macrophages. J Bone Miner Res: Off J Am Soc Bone Miner Res 2:135–142CrossRef
22.
go back to reference Schliep S, Schuler G, Kiesewetter F (2008) Successful treatment of calciphylaxis with pamidronate. Eur J Dermatol: EJD 18:554–556PubMed Schliep S, Schuler G, Kiesewetter F (2008) Successful treatment of calciphylaxis with pamidronate. Eur J Dermatol: EJD 18:554–556PubMed
Metadata
Title
Nonuremic calciphylaxis precipitated by teriparatide [rhPTH(1–34)] therapy in the setting of chronic warfarin and glucocorticoid treatment
Authors
E. K. Spanakis
D. E. Sellmeyer
Publication date
01-04-2014
Publisher
Springer London
Published in
Osteoporosis International / Issue 4/2014
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-013-2580-6

Other articles of this Issue 4/2014

Osteoporosis International 4/2014 Go to the issue